Company: RGNT
Filing Date: 2025-07-07
Form Type: F-1/A
Source: 0001213900-25-061821
Chunk: 286

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-07-07
Form: F-1/A
Chunk 286
---
 valuation
of $5.15 million, the 2020 CLAs shall be automatically converted into 243,955 Ordinary Shares and the Additional Amount in addition to
the Risk Premium (each as defined therein) shall be automatically converted into 221,456 Ordinary Shares, which will occur upon the completion
of this offering. As of July 7, 2024, the Company received $450,000 in proceeds.

In September 2021, we entered
into several convertible loan agreements entered into in September 2021, or the 2021 CLAs, pursuant to which we obtained a convertible
loan in the aggregate amount of $835,000. In connection with the 2021 CLAs, the lenders were granted warrants to purchase shares of the
Company of the same class of the conversion securities. Effective as of March 11, 2024, the 2021 CLAs were converted into 35,354 Ordinary
Shares and the warrants granted thereunder expired in full in December 2023.

Between October 2024 and
November 2024, we entered into Bridge Loans, pursuant to which we obtained a bridge loan from certain lenders, including certain related
parties. In October 2024, we amended the Bridge Loans pursuant to which the Bridge Loans have been extended until August 31, 2025 and
shall bear interest at 8% per annum until maturity commencing as of September 1, 2024. Furthermore, upon the occurrence of a Qualified
IPO, the Bridge Loan lenders, shall be granted warrants to purchase such number of Ordinary Shares equal to 140,000 Ordinary Shares following
the consummation of this offering.

Between December 2023
and January 2024, we entered into the 2024 Loan Agreements pursuant to which we obtained a loan in the aggregate amount of $150,000 from
certain lenders, including certain related parties. In October 2024, we amended the 2024 Loan Agreements pursuant to which the 2024 Loan
Agreements have been extended until August 31, 2025, and shall bear interest at 8% per annum until maturity commencing as of September
1, 2024. Furthermore, upon the occurrence of a Qualified IPO, the 2024 Loan Agreements lenders, shall be granted warrants to purchase
such number of Ordinary Shares equal to two times their respective loan amount in addition to a risk premium based on a price per share
equal to 61,